Cetuximab is approved for treatment of metastatic colorectal cancers expressing ErbB1, for locally advanced squamous cell carcinoma of the head and neck and in non-small-cell lung cancer (NSCLC). This evidence concerns the gene EGFR and metastatic colorectal cancer.